{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:18Z","timestamp":1792165098641,"version":"4.4.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case series<\/jats:title><jats:p>We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Long-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1528457","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:43:53Z","timestamp":1737438233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Andrijana","family":"Koceva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Mleku\u0161 Kozamernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Jane\u017e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ferjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac082","article-title":"Approach to the patient with prader\u2013willi syndrome","volume":"107","author":"H\u00f6ybye","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00002-4","article-title":"Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction","volume":"9","author":"Tauber","year":"2021","journal-title":"Lancet Diabetes Endocrinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104379","DOI":"10.1016\/j.ejmg.2021.104379","article-title":"The consequences of hyperphagia in people with Prader-Willi Syndrome: A systematic review of studies of morbidity and mortality","volume":"65","author":"Bellis","year":"2022","journal-title":"Eur J Med Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.178","article-title":"Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey","volume":"19","author":"Butler","year":"2017","journal-title":"Genet Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2006)111[193:MIPS]2.0.CO;2","article-title":"Mortality in prader-willi syndrome","volume":"111","author":"Einfeld","year":"2006","journal-title":"Am J Ment Retard"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2011.02225.x","article-title":"Prader\u2013Willi syndrome in Victoria: Mortality and causes of death","volume":"48","author":"Lionti","year":"2012","journal-title":"J Paediatrics Child Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2010.139","article-title":"Development of the eating behaviour in Prader\u2013Willi Syndrome: advances in our understanding","volume":"35","author":"McAllister","year":"2011","journal-title":"Int J Obes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803128","article-title":"Neural representations of hunger and satiety in Prader\u2013Willi syndrome","volume":"30","author":"Hinton","year":"2006","journal-title":"Int J Obes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"fcac229","DOI":"10.1093\/braincomms\/fcac229","article-title":"In vivo neuroimaging evidence of hypothalamic alteration in Prader\u2013Willi syndrome","volume":"4","author":"Brown","year":"2022","journal-title":"Brain Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.039024","article-title":"Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI","volume":"76","author":"Shapira","year":"2005","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/diseases3040382","article-title":"Puzzle pieces: neural structure and function in prader-willi syndrome","volume":"3","author":"Manning","year":"2015","journal-title":"Diseases"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2006.118","article-title":"Neural mechanisms underlying hyperphagia in prader-willi syndrome","volume":"14","author":"Holsen","year":"2006","journal-title":"Obesity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2011.204","article-title":"Importance of reward and prefrontal circuitry in hunger and satiety: Prader\u2013Willi syndrome vs simple obesity","volume":"36","author":"Holsen","year":"2012","journal-title":"Int J Obes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3945\/an.117.016253","article-title":"Energy metabolism profile in individuals with prader-willi syndrome and implications for clinical management: A systematic review","volume":"8","author":"Alsaif","year":"2017","journal-title":"Adv Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00386-X","article-title":"Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi Syndrome","volume":"143","author":"Bekx","year":"2003","journal-title":"J Pediatrics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01574-9","article-title":"Obesity in Prader\u2013Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches","volume":"44","author":"Muscogiuri","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2011.06.001","article-title":"In adults with Prader\u2013Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels","volume":"45","author":"Purtell","year":"2011","journal-title":"Neuropeptides"},{"key":"B18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-09-1033","article-title":"Children with Prader\u2013Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children","volume":"162","author":"Bizzarri","year":"2010","journal-title":"Eur J Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2004.17.9.1177\/html","article-title":"Plasma peptide YY and ghrelin levels in infants and children with prader-willi syndrome","volume":"17","author":"Butler","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.a.v167.1","article-title":"Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia","volume":"167","author":"Kweh","year":"2015","journal-title":"Am J Med Genet Pt A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2503","article-title":"Macronutrient regulation of ghrelin and peptide YY in pediatric obesity and prader-willi syndrome","volume":"100","author":"Gumus Balikcioglu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510457","article-title":"Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment","volume":"151","author":"Hoybye","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14583","article-title":"The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader\u2013Willi syndrome: A systematic review","volume":"96","author":"Ng","year":"2022","journal-title":"Clin Endocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.886704","article-title":"The ventral tegmental area and nucleus accumbens as circadian oscillators: implications for drug abuse and substance use disorders","volume":"13","author":"Becker-Krail","year":"2022","journal-title":"Front Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21387","article-title":"Effects of liraglutide in hypothalamic arcuate nucleus of obese mice","volume":"24","author":"Barreto-Vianna","year":"2016","journal-title":"Obesity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ12-0074","article-title":"The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome","volume":"59","author":"Senda","year":"2012","journal-title":"Endocr J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03280.x","article-title":"Liraglutide therapy in Prader-Willi syndrome","volume":"28","author":"Cyganek","year":"2011","journal-title":"Diabetic Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.29.81","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report","volume":"29","author":"Sano","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0389","article-title":"Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report","volume":"33","author":"Candler","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2020.25.1.52","article-title":"Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome","volume":"25","author":"Kim","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2575","article-title":"Use of GLP-1 receptor agonists in prader-willi syndrome: report of six cases","volume":"37","author":"Fintini","year":"2014","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12020-022-03064-1","article-title":"Intensive management of obesity in people with Prader-Willi syndrome","volume":"77","author":"Nolan","year":"2022","journal-title":"Endocrine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for weight management in children and adolescents with prader\u2013willi syndrome and obesity","volume":"108","author":"Diene","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/1871530322666220509225637","article-title":"Effects of semaglutide on glycemic control and weight loss in a patient with prader-willi syndrome: A case report","volume":"22","author":"Sani","year":"2022","journal-title":"EMIDDT"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2023.12.001","article-title":"Effect of semaglutide on weight loss and glycaemic control in patients with Prader\u2013Willi Syndrome and type 2 diabetes","volume":"71","author":"Gim\u00e9nez-Palop","year":"2024","journal-title":"Endocrinolog\u00eda Diabetes y Nutrici\u00f3n (English ed)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11892-020-1284-5","article-title":"Update on diabetes mellitus and glucose metabolism alterations in prader-willi syndrome","volume":"20","author":"Crin\u00f2","year":"2020","journal-title":"Curr Diabetes Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13023-022-02344-3","article-title":"Do patients with Prader\u2013Willi syndrome have favorable glucose metabolism","volume":"17","author":"Qian","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/jcm10122667","article-title":"Twenty years of GH treatment in adults with prader-willi syndrome","volume":"10","author":"Sj\u00f6str\u00f6m","year":"2021","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14372","article-title":"The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review","volume":"94","author":"Frixou","year":"2021","journal-title":"Clin Endocrinology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3607","article-title":"Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome","volume":"99","author":"Lafortuna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2005.00641.x","article-title":"Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome","volume":"49","author":"H\u00f6ybye","year":"2005","journal-title":"J Intellect Disabil Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2006.00878.x","article-title":"Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study","volume":"51","author":"Bertella","year":"2007","journal-title":"J Intellect Disabil Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1198616","article-title":"Long-term effects of GH therapy in adult patients with Prader-Willi syndrome: a longitudinal study","volume":"14","author":"Grugni","year":"2023","journal-title":"Front Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/j.sempedsurg.2013.10.013","article-title":"Bariatric surgery in monogenic and syndromic forms of obesity","volume":"23","author":"Alqahtani","year":"2014","journal-title":"Semin Pediatr Surgery"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12575","article-title":"Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: Long term results for up to 10 years","volume":"15","author":"Liu","year":"2020","journal-title":"Pediatr Obes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2015.07.014","article-title":"Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study","volume":"12","author":"Alqahtani","year":"2016","journal-title":"Surg Obes Related Diseases"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1381\/096089201321209404","article-title":"Outcome of biliopancreatic diversion in subjects with prader-willi syndrome","volume":"11","author":"Marinari","year":"2001","journal-title":"Obes Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"B58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.ijo.0801083","article-title":"Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies","volume":"24","author":"Flint","year":"2000","journal-title":"Int J Obes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1528457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:43:56Z","timestamp":1737438236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1528457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":58,"alternative-id":["10.3389\/fendo.2024.1528457"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1528457","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"1528457"}}